Immunogenicity of a two-dose regime of varicella vaccine in children with cancers
- PMID:15059071
- DOI: 10.1111/j.1600-0609.2004.00216.x
Immunogenicity of a two-dose regime of varicella vaccine in children with cancers
Abstract
Objective: Live-attenuated varicella vaccine is effective and safe in immunocompetent children. In this study, we assess the immunogenicity and adverse events following varicella vaccination in immunosuppressed cancer children.
Methods: Varicella-zoster virus (VZV)-seronegative cancer children received two doses of live-attenuated VZV vaccine (Varilrix) in a span of 3 months. Patients with acute lymphoblastic leukaemia (ALL) were in the maintenance phase of chemotherapy, whereas those with solid tumours joined the study around 3-6 months from treatment discontinuation. VZV-specific cellular and humoral immune responses were measured before and after VZV vaccination.
Results: The median (range) age of the 17 patients was 4.4 yr (2.0-14.5). Thirteen had ALL, one had myelodysplastic syndrome and three had solid tumours. Following vaccination, the VZV-specific stimulation index (SI) increased from 1.7 (0.9-2.9) to 17.9 (5.9-36.0) (P < 0.001). Similarly, SI to phytohaemagglutinin mitogen increased from 1136 (499-1930) to 1714 (848-2518) (P = 0.028). There were also significant increases in CD4+ cells and CD4:CD8 ratio as well as a reduction in CD16/56+ cells in peripheral blood lymphocytes. Seroconversion rate to VZV was 19% after one dose and increased to 94% after the second dose of VZV vaccine. Serum VZV-specific IgG concentrations also increased significantly following two doses when compared with one dose of VZV vaccine (P = 0.0004). One subject developed possibly vaccine-related chickenpox with self-limiting hepatitis at 5 wk following vaccination. None of the patients developed herpes-zoster at a median (range) follow-up of 27.5 months (24.0-30.0).
Conclusions: Non-immune cancer children can be effectively vaccinated against chickenpox at the defined period. However, the safety of chickenpox vaccine in these immunosuppressed children needs to be further studied.
Copyright Blackwell Munksgaard 2004.
Similar articles
- Varicella vaccination in HIV-1-infected children after immune reconstitution.Bekker V, Westerlaken GH, Scherpbier H, Alders S, Zaaijer H, van Baarle D, Kuijpers T.Bekker V, et al.AIDS. 2006 Nov 28;20(18):2321-9. doi: 10.1097/QAD.0b013e3280113f29.AIDS. 2006.PMID:17117018
- Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells.Levin MJ, Gershon AA, Weinberg A, Song LY, Fentin T, Nowak B; Pediatric AIDS Clinical Trials Group 265 Team.Levin MJ, et al.J Infect Dis. 2006 Jul 15;194(2):247-55. doi: 10.1086/505149. Epub 2006 Jun 14.J Infect Dis. 2006.PMID:16779732Clinical Trial.
- Vaccination of children with malignant disease against varicella.Slørdahl SH, Wiger D, Strømøy T, Degre M, Thørsby E, Lie SO.Slørdahl SH, et al.Postgrad Med J. 1985;61 Suppl 4:85-92.Postgrad Med J. 1985.PMID:3014484
- Humoral and cell-mediated immune responses in children and adults after 1 and 2 doses of varicella vaccine.Watson B.Watson B.J Infect Dis. 2008 Mar 1;197 Suppl 2:S143-6. doi: 10.1086/522130.J Infect Dis. 2008.PMID:18419388Review.
- The safety profile of varicella vaccine: a 10-year review.Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, Gershon AA, Sharrar RG.Galea SA, et al.J Infect Dis. 2008 Mar 1;197 Suppl 2:S165-9. doi: 10.1086/522125.J Infect Dis. 2008.PMID:18419392Review.
Cited by
- COVID-19 vaccination in cancer patients: a narrative review.Seneviratne SL, Yasawardene P, Wijerathne W, Somawardana B.Seneviratne SL, et al.J Int Med Res. 2022 Mar;50(3):3000605221086155. doi: 10.1177/03000605221086155.J Int Med Res. 2022.PMID:35313761Free PMC article.Review.
- Practical review of immunizations in adult patients with cancer.Ariza-Heredia EJ, Chemaly RF.Ariza-Heredia EJ, et al.Hum Vaccin Immunother. 2015;11(11):2606-14. doi: 10.1080/21645515.2015.1062189. Epub 2015 Jun 25.Hum Vaccin Immunother. 2015.PMID:26110220Free PMC article.Review.
- Precision immunization: a new trend in human vaccination.Jia S, Li J, Liu Y, Zhu F.Jia S, et al.Hum Vaccin Immunother. 2020 Mar 3;16(3):513-522. doi: 10.1080/21645515.2019.1670123. Epub 2020 Jan 29.Hum Vaccin Immunother. 2020.PMID:31545124Free PMC article.Review.
- Guidelines on vaccinations in paediatric haematology and oncology patients.Cesaro S, Giacchino M, Fioredda F, Barone A, Battisti L, Bezzio S, Frenos S, De Santis R, Livadiotti S, Marinello S, Zanazzo AG, Caselli D.Cesaro S, et al.Biomed Res Int. 2014;2014:707691. doi: 10.1155/2014/707691. Epub 2014 Apr 29.Biomed Res Int. 2014.PMID:24868544Free PMC article.Review.
- Herpesvirus infections of the central nervous system in immunocompromised patients.Meyding-Lamadé U, Strank C.Meyding-Lamadé U, et al.Ther Adv Neurol Disord. 2012 Sep;5(5):279-96. doi: 10.1177/1756285612456234.Ther Adv Neurol Disord. 2012.PMID:22973424Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials